08:00 , Dec 20, 2010 |  BC Week In Review  |  Company News

ARYx gastrointestinal, cardiovascular news

ARYx terminated all of its employees, including officers, after FDA delayed to 1Q11 a response to an SPA submitted for naronapride ( ATI-7505). ARYx said it was not able to obtain financing to continue operations...
07:00 , Apr 5, 2010 |  BioCentury  |  Finance

Restructuring Watch

Restructuring Watch Date Company Staff cuts Cash Years cash pre-cut Cash date 12-mo op loss ended 12/31/09 1/7/10 Molecular Insight Pharmaceuticals Inc. (NASDAQ:MIPI) 13% to 61...
08:00 , Feb 22, 2010 |  BioCentury  |  Finance

Ebb & Flow

Amgen Inc. (NASDAQ:AMGN) gained $0.90 to $57.38 last week after FDA approved a REMS for the use of erythropoiesis-stimulating agents (ESAs) in cancer patients. Amgen markets Aranesp darbepoetin alfa for cancer and renal indications and...
08:00 , Feb 22, 2010 |  BC Week In Review  |  Company News

ARYx cardiovascular, neurology, gastrointestinal news

ARYx reduced headcount to fewer than 20 and hired Cowen and Co. to explore strategic options after partnering discussions for budiodarone fell through. The anti-arrhythmic amiodarone analog has completed a Phase IIb trial to...
08:00 , Jan 4, 2010 |  BioCentury  |  Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Years cash pre-cut Cash date Oper loss for 9 mos ended 9/30 10/28/09 SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) 17% to...
08:00 , Nov 2, 2009 |  BC Week In Review  |  Company News

ARYx cardiovascular news

ARYx restructured and reduced headcount by 17 (23%) to 56 with cuts companywide to focus on out-licensing its late stage compounds, including budiodarone. The anti-arrhythmic amiodarone analog has completed a Phase IIb trial to...
07:00 , Aug 3, 2009 |  BioCentury  |  Strategy

What might fit

What might fit Company Product Description Indication Status Arca biopharma Inc. (NASDAQ:ABIO) Gencaro bucindolol Non-selective beta blocker Chronic heart failure FDA complete response letter...
07:00 , Aug 3, 2009 |  BioCentury  |  Strategy

Questions of the heart

On its way to becoming a bellwether biotech, Gilead Sciences Inc. saw its market cap jump some 50% in less than two years, climbing from about $26 billion in early 2006 to about $40 billion...
07:00 , Jul 13, 2009 |  BioCentury  |  Product Development

The real world must wait

There some indications where it is hard to get new drugs approved, despite the obvious need, because patients on traditional treatments do so much better in the rigorous setting of a clinical trial than they...
07:00 , Jul 6, 2009 |  BioCentury  |  Finance

3rd Quarter Stock Preview: Making the Milestone

Buysiders expect the summer months, as always, to be a little light on events. While some are hoping for a few dramatic upside moves among some neglected small caps, most buysiders were hesitant to disclose...